Literature DB >> 6953221

A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.

J R Priest, N K Ramsay, P G Steinherz, D G Tubergen, M S Cairo, A L Sitarz, A J Bishop, L White, M E Trigg, C J Levitt, J A Cich, P F Coccia.   

Abstract

L-Asparaginase therapy for childhood acute lymphoblastic leukemia causes deficiencies of plasma hemostatic proteins, especially antithrombin, plasminogen, and fibrinogen. Severe thromboses and hemorrhages occurred in 18 children receiving vincristine, prednisone, and asparaginase therapy for ALL. Thirteen children had intracranial thrombosis or hemorrhage, four had extremity thrombosis, and one had both an intracranial hemorrhage and an extremity thrombosis. These events occur characteristically in the third and fourth weeks of therapy during or just after a three-week course of L-asparaginase. Symptoms of headache, obtundation, hemiparesis, and seizure were common for the intracranial events: local pain, swelling, and discoloration were common for the extremity thromboses. These complications have been recognized in 1 to 2% of children undergoing induction therapy which includes asparaginase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953221     DOI: 10.1016/s0022-3476(82)80535-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Identification of functional regions in the Rhodospirillum rubrum L-asparaginase by site-directed mutagenesis.

Authors:  M V Pokrovskaya; S S Aleksandrova; V S Pokrovsky; A V Veselovsky; D V Grishin; O Yu Abakumova; O V Podobed; A A Mishin; D D Zhdanov; N N Sokolov
Journal:  Mol Biotechnol       Date:  2015-03       Impact factor: 2.695

3.  Clotting complications of L-asparaginase therapy in children with ALL.

Authors:  M G Cappellato; A Rosolen; L Zanesco; A Girolami
Journal:  Blut       Date:  1986-06

4.  Subacute leukoencephalopathy complicating acute lymphoblastic leukemia.

Authors:  F M Filloux; J J Townsend
Journal:  West J Med       Date:  1987-02

5.  Neurosurgical management of L-asparaginase induced haemorrhagic stroke.

Authors:  Elisha Ogbodo; Chandrasekaran Kaliaperumal; Michael O'Sullivan
Journal:  BMJ Case Rep       Date:  2012-03-08

6.  The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Authors:  Rachael F Grace; Suzanne E Dahlberg; Donna Neuberg; Stephen E Sallan; Jean M Connors; Ellis J Neufeld; Daniel J Deangelo; Lewis B Silverman
Journal:  Br J Haematol       Date:  2011-01-07       Impact factor: 6.998

7.  Coagulation factors and proteinase inhibitors in the plasma of children with acute lymphoblastic leukoses. Behaviour before and during treatment according to Protocol I of the Cooperative Leukaemia Study COALL-80.

Authors:  M Reitz; G Witzke; R Egbring; P Gutjahr
Journal:  Klin Wochenschr       Date:  1984-12-17

Review 8.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

9.  Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.

Authors:  Alessandra Erbetta; Andrea Salmaggi; Angelo Sghirlanzoni; Antonio Silvani; Paolo Potepan; Andrea Botturi; Elisa Ciceri; Maria Grazia Bruzzone
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

10.  Lesions of the central nervous system in leukemia: Pathological and magnetic resonance imaging features at presentation in 14 patients.

Authors:  Jing Liu; Yaming Wang; Xuefei Sun; Shuo Liu; Zhenkun Yu; Nan Ji; Shengjun Sun; Yuanbo Liu
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.